US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Ready Capital Corp

24.47

0.0000

Volume:- -

Turnover:17.13K

Market Cap:- -

PE:- -

High:24.47

Open:24.47

Low:24.47

Close:24.47

Loading ...

Overview Company News Filings

Buy Rating for Trevi Therapeutics Driven by Promising Haduvio Trial Results and Strong Efficacy in RCC and IPF Cough

Merck Breaks Ground on New $1 Billion Biologics Center of Excellence in Wilmington, Delaware

KEYTRUDA® (pembrolizumab) as Perioperative Treatment With Standard of Care (SOC) Adjuvant Therapy Significantly Improved Event-Free Survival Compared to SOC Alone in Patients With Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

Titan America Wins Industry Award for Low Carbon Concrete Project at Marine Terminal in Chesapeake

Trevi Therapeutics to Participate in Upcoming April Investor Conferences

National Cancer Center Japan and PeptiDream: New Radiopharmaceuticals for Renal Cell Carcinoma

Bristol Myers Squibb Receives Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo® (nivolumab) Across Multiple Solid Tumor Indications

Sensei Biotherapeutics Reports Favorable Preliminary Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors

FDA Expands Exelixis Cabometyx Label for Neuroendocrine Tumors

Junshi Biosciences Announces Toripalimab’s Approval in Singapore

Exelixis Stock Rises 13.3% Year to Date: Buy, Sell or Hold?

Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors

New Money Smart Financial Coaching Program (MSFCP) Organization Empowers College Students to Take Control of Their Financial Futures with Support from JPMorganChase

Press Release: Trevi Therapeutics Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Updates

Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2024 and Provides a Business Update

Allogene Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update

Trevi Therapeutics to Report Fourth Quarter and Year End 2024 Financial Results and Provide a Corporate Update on March 18, 2025

TRVI Stock Soars on Meeting Primary Goal in Chronic Cough Study

Haduvio’s Promising Efficacy in RCC Drives Buy Rating and Increased Price Target

Trevi Therapeutics Announces Positive Topline Results from the Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/RCC/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"RCC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RCC\",,,,,undefined,":{"symbol":"RCC","market":"US","secType":"STK","nameCN":"Ready Capital Corp","latestPrice":24.465,"timestamp":1750254994850,"preClose":24.465,"halted":0,"volume":0,"delay":0,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Trading","change":0,"latestTime":"06-18 09:56:34 EDT","open":24.465,"high":24.465,"low":24.465,"amount":17132.28729,"amplitude":0,"askPrice":24.74,"askSize":120,"bidPrice":23.93,"bidSize":100,"shortable":3,"etf":0,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1750276800000},"marketStatusCode":2,"adr":0,"exchange":"NYSE","adjPreClose":24.465,"dividendRate":0.058758,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RCC\",,,,,undefined,":{"symbol":"RCC","floatShares":0,"roa":"-2.31%","roe":"-11.15%","lyrEps":0,"shares":0,"dividePrice":1.43752,"high":24.465,"amplitude":0,"preClose":24.465,"low":24.465,"week52Low":23.85,"pbRate":"0.00","psRate":"0.00","week52High":26.87,"institutionHeld":0,"latestPrice":24.465,"committee":-0.090909,"eps":0,"divideRate":0.058758,"volume":0,"delay":0,"ttmEps":0,"open":24.465,"prevYearClose":24.42,"prevWeekClose":24.38,"prevMonthClose":23.97,"prevQuarterClose":24.75,"fiveDayClose":24.39,"twentyDayClose":24.5,"sixtyDayClose":24.65},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RCC\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2536299615","title":"Buy Rating for Trevi Therapeutics Driven by Promising Haduvio Trial Results and Strong Efficacy in RCC and IPF Cough","url":"https://stock-news.laohu8.com/highlight/detail?id=2536299615","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536299615?lang=en_us&edition=fundamental","pubTime":"2025-05-20 18:16","pubTimestamp":1747736207,"startTime":"0","endTime":"0","summary":"Trevi Therapeutics (TRVI – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Serge Belanger fr...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/buy-rating-for-trevi-therapeutics-driven-by-promising-haduvio-trial-results-and-strong-efficacy-in-rcc-and-ipf-cough?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/buy-rating-for-trevi-therapeutics-driven-by-promising-haduvio-trial-results-and-strong-efficacy-in-rcc-and-ipf-cough?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RCC","LENZ"],"gpt_icon":0},{"id":"2531869477","title":"Merck Breaks Ground on New $1 Billion Biologics Center of Excellence in Wilmington, Delaware","url":"https://stock-news.laohu8.com/highlight/detail?id=2531869477","media":"Business Wire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531869477?lang=en_us&edition=fundamental","pubTime":"2025-04-29 18:45","pubTimestamp":1745923500,"startTime":"0","endTime":"0","summary":"Merck Wilmington Biotech will serve as a launch and commercial production facility and the future U.S. home for KEYTRUDA. RAHWAY, N.J., April 29, 2025----Merck , known as MSD outside of the United States and Canada, announced today the start of construction for a $1 billion, 470,000-square-foot state-of-the-art biologics center of excellence in Wilmington, Delaware.A cornerstone of Merck’s continued commitment to investing in American innovation and infrastructure, Merck Wilmington Biotech will comprise laboratory, manufacturing and warehouse capabilities to enable the launch and commercial production of next-generation biologics and therapies including potent antibody-drug conjugates , reinforcing Merck’s focus on expanding and diversifying its pipeline.With proximity to Delaware and Pennsylvania universities, Merck Wilmington Biotech will also attract talented students and professionals, supporting community growth and development. The site’s proximity to Merck’s existing facilities ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/merck-breaks-ground-1-billion-104500898.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4135","CRT","LU1066051811.HKD","LU1116320737.USD","LU1929549753.HKD","BK4516","LU0965509283.SGD","CPS","LU1585245621.USD","BK4585","LU0211331839.USD","LU1035773651.USD","LU2361045086.USD","BK4559","RCC","LU1291159041.SGD","SG9999002224.SGD","LU0208291251.USD","BK4588","ALT","LU0320765646.SGD","MRK","LU0965509010.AUD","BK4533","LU0965508806.USD","LU2468319806.SGD","LU0861579265.USD","LU1066053197.SGD","LU1069347547.HKD","LU1983299246.USD","BCG","LU1066051498.USD","LU2324357040.USD","CRC","HSCT","LU0265550946.USD","LU1116320901.HKD","IE00B4R5TH58.HKD","IE00B2B36J28.USD","LU1023059063.AUD","LU2023250504.SGD","LU1974910355.USD","BK4161","HCC","SG9999001440.SGD","SG9999015341.SGD","BTC","LU0122379950.USD","DM","IE00BJT1NW94.SGD"],"gpt_icon":0},{"id":"2530548354","title":"KEYTRUDA® (pembrolizumab) as Perioperative Treatment With Standard of Care (SOC) Adjuvant Therapy Significantly Improved Event-Free Survival Compared to SOC Alone in Patients With Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2530548354","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530548354?lang=en_us&edition=fundamental","pubTime":"2025-04-28 00:00","pubTimestamp":1745769600,"startTime":"0","endTime":"0","summary":"KEYNOTE-689 marks the first positive trial in more than two decades for patients with resected locally advanced head and neck squamous cell carcinoma . Results to be presented at American Association for Cancer Research  Annual Meeting 2025 during a Plenary Session and included in official meeting press program. \"As the first positive trial in over two decades for patients with resectable, locally advanced head and neck squamous cell carcinoma, the presentation of these landmark results marks an important moment for these patients and those who care for them,\" said Dr. Ravindra Uppaluri, the study’s co-principal investigator, director of Head and Neck Surgical Oncology, Brigham and Women’s Hospital and Dana-Farber","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/keytruda-pembrolizumab-perioperative-treatment-standard-160000135.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0265550946.USD","ON","SG9999001440.SGD","LU1934455194.USD","LU0320765646.SGD","LU2298322129.HKD","LU2106854487.HKD","LU1430594728.SGD","BCG","MRK","SMP","SG9999014567.USD","BK4161","LU0861579265.USD","LU1066051225.USD","RCC","SGXZ57979304.SGD","ALT","IE0009355771.USD","LU1854103824.USD","SOC","LU1037948541.HKD","CRT","LU1861220033.SGD","BK4135","LU0320765489.SGD","ITT","DM","CPS","HCC","LU0289739699.SGD","BK4605","OS","SG9999015358.SGD","LU0208291251.USD","BK4097","IE00B7SZL793.SGD","AEIS","BK4533","IE00BLSP4239.USD","LU2361044949.HKD","HSCT","LU0054578231.USD","CRC","IE00BZ199S13.USD","LU2023250843.SGD","LU1162221912.USD","IE00BLSP4452.SGD","LU2361044865.SGD","BTC"],"gpt_icon":0},{"id":"2525899371","title":"Titan America Wins Industry Award for Low Carbon Concrete Project at Marine Terminal in Chesapeake","url":"https://stock-news.laohu8.com/highlight/detail?id=2525899371","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525899371?lang=en_us&edition=fundamental","pubTime":"2025-04-08 20:00","pubTimestamp":1744113600,"startTime":"0","endTime":"0","summary":"\"Norfapeake\" Terminal, a marine terminal operated as an affiliate of Titan America / Roanoke Cement in Chesapeake, VA.The Norfapeake marine terminal in Chesapeake was recently enhanced with a cement storage dome capable of housing approximately 70,000 tonnes of cement, as well as increased trucking and rail capacity to meet the demand for its low-carbon cements. TVRM and RCC used this major investment as an opportunity to prove out the latest cement technology at scale and under harsh conditions. The performance of Type IT cement was crucial because the terminal abuts the brackish water of the Elizabeth River and is subject to freezing and thawing cycles and receives de-icing salts throughout the winter to maintain the 24/7 load out traffic.Type IT cement was first introduced in 2023 and represents the company’s next generation of cement, marketed under the \"Titan E","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/titan-america-wins-industry-award-120000654.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4011","RCC","TTAM"],"gpt_icon":0},{"id":"2524253267","title":"Trevi Therapeutics to Participate in Upcoming April Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2524253267","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524253267?lang=en_us&edition=fundamental","pubTime":"2025-04-03 19:30","pubTimestamp":1743679800,"startTime":"0","endTime":"0","summary":"NEW HAVEN, Conn., April 3, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio  for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis  and refractory chronic cough ,today announced that senior management will be participating in the following investor conferences in April.Refractory chronic cough has no approved therapies in the U.S. and is defined as a persistent cough lasting >8weeks despite treatment for an underlying condition  and includes unexplained chronic cough. RCC affects ~2-3 million patients in the U.S. and is caused by cough reflex hypersensitivity in both the central and peripheral nerves. It is a highly debilitating dise","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/trevi-therapeutics-participate-upcoming-april-113000321.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/trevi-therapeutics-participate-upcoming-april-113000321.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["RCC","TRVI","LENZ","BK4007","BK4139"],"gpt_icon":0},{"id":"2522576330","title":"National Cancer Center Japan and PeptiDream: New Radiopharmaceuticals for Renal Cell Carcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2522576330","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522576330?lang=en_us&edition=fundamental","pubTime":"2025-03-28 20:00","pubTimestamp":1743163200,"startTime":"0","endTime":"0","summary":"-Assessing the potential of PD-32766 as a PET diagnostic and raising expectations for novel diagnostic and therapeutic agents in nuclear medicine-. The first-in-human PET imaging trial of 64Cu-PD-32766 for patients with clear cell renal cell carcinoma  was conducted at the National Cancer Center Hospital East and promising results were obtained.PET positive rate: 64Cu-PD-32766 was confirmed to clearly accumulate in the lesion sites, with a PET positive rate of 95% by lesion, suggesting promising utility as a diagnostic agent.Pharmacokinetics: Blood concentration of 64Cu-PD-32766 dropped sharply within 5 minutes after administration, indicating good clearance from the bloodstream while maintaining accumulation in lesion sites.RCC is a disease with a poor prognosis, which necessitates the establishment of novel diagnosis and therapeutic methods. CA9 is a cell surface antigen highly expressed in ~95% of ccRCC with minimal expression in normal tissues, making it an attractive target for di","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/national-cancer-center-japan-peptidream-120000312.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0368265418.SGD","LU0300736492.USD","BK4139","MPC","RCC","PPTDF","LU0122376428.USD","LU0266512127.USD","LU0788109394.HKD","LU0456854461.SGD","BK4585","BK4138","NHLD","BK4588","LU0300736062.USD","LU0170899867.USD","IE00BSNM7G36.USD"],"gpt_icon":0},{"id":"2522257316","title":"Bristol Myers Squibb Receives Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo® (nivolumab) Across Multiple Solid Tumor Indications","url":"https://stock-news.laohu8.com/highlight/detail?id=2522257316","media":"Business Wire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522257316?lang=en_us&edition=fundamental","pubTime":"2025-03-28 20:00","pubTimestamp":1743163200,"startTime":"0","endTime":"0","summary":"Recommendation is based primarily on results from the Phase 3 CheckMate -67T trial which demonstrated noninferiority in the co-primary endpoints of Cavgd28 and Cminss and consistent efficacy in the secondary endpoint of overall response rate for the subcutaneous formulation of Opdivo vs. its intravenous formulation. A decision on the EU Opdivo extension of marketing authorization is expected by June 2, 2025. \"The positive CHMP opinion is an important step forward in the evolution of immuno-oncology and in the potential of subcutaneous nivolumab to help transform the lives of people living with cancer,\" said Dana Walker, M.D., M.S.C.E., Opdivo global program lead, Bristol Myers Squibb. \"We look forward to bringing the same high-quality care that transformed cancer treatment with an administration method that has the potential to improve the patient experience and efficiency of healthcare systems in Europe.\"","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bristol-myers-squibb-receives-positive-120000105.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MYE","HSCT","VOD","LU1670711040.USD","LU1868836914.USD","LU1291159041.SGD","TEN","LU0868494617.USD","IE00BJJMRZ35.SGD","EEA","LU0237698245.USD","LU1670711123.USD","LU2242652126.USD","LU0306807586.USD","ORR","BK4532","UK","RCC","BK4528","LU0321505439.SGD","LU1670710661.SGD","BK4156","LU1093756325.SGD","BK4007","LU1718418525.SGD","LU0061475181.USD","LU1032466523.USD","IE0002141913.USD","LU0882574055.USD","LU1323610961.USD","CHMP","LU0456855351.SGD","LU1670710588.SGD","BK4008","BK4585","IE00BFTCPJ56.SGD","LU1261432733.SGD","EC","BK4534","BMY","ALK","CRT","LU1074936037.SGD","LU0096364046.USD","LU2133065610.SGD","BK4559","IE0009355771.USD","LU1093756168.USD","BK4500"],"gpt_icon":0},{"id":"2522558078","title":"Sensei Biotherapeutics Reports Favorable Preliminary Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2522558078","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522558078?lang=en_us&edition=fundamental","pubTime":"2025-03-28 04:05","pubTimestamp":1743105900,"startTime":"0","endTime":"0","summary":"– Initial clinical activity in a PD-1 resistant population, with an ORR almost three times higher than historical PD-1 rechallenge response rates, with data still maturing –。– One durable complete response in a Merkel Cell Carcinoma  patient and two partial responses , including one in a second MCC patient and one in a microsatellite instability-high  Colorectal Cancer  patient, all of whom were previously treated with and progressed on immunotherapy –。– All PD-1 resistant “hot” tumor patients with tumor shrinkage remain on study, suggesting potential for deepening responses over time –。The Phase 1 dose expansion trial is a multi-center, open-label, dose expansion study evaluating solnerstotug as monotherapy and in combination withLibtayo , Regeneron’s PD-1 inhibitor, in both a basket of “hot” tumorsthat typically respond to immunotherapy but have progressed on prior PD-1 therapy and a single “cold” tumor histology  that is typically unresponsive to immunotherapy.At the time of this da","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/sensei-biotherapeutics-reports-favorable-preliminary-200500147.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0266512127.USD","IE00B7SZL793.SGD","CRS","CRC","MSS","PR","BK4023","BK4139","BK4588","L","SITC","BK4113","LU1169590202.USD","BK4107","IE00B66KJ199.SGD","SNSE","BK4585","BK4006","CR","LU0053666078.USD","LU1169589451.USD","LU0456854461.SGD","LU2065731478.USD","IE00B19Z4B17.USD","BK4161","BK4231","IE0031619046.USD","SD","PD","RCC","BK4080","BK4213"],"gpt_icon":0},{"id":"2522537272","title":"FDA Expands Exelixis Cabometyx Label for Neuroendocrine Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2522537272","media":"Zacks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522537272?lang=en_us&edition=fundamental","pubTime":"2025-03-28 03:00","pubTimestamp":1743102000,"startTime":"0","endTime":"0","summary":"Exelixis, Inc. EXEL announced that the FDA has approved the label expansion of its lead drug Cabometyx .The regulatory body approved Cabometyx for the treatment of adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic neuroendocrine tumors .Simultaneously, the drug was approved for adult and pediatric patients  with previously treated, unresectable, locally advanced or metastatic, well-differentiated extra-pancreatic NET .Consequently, Cabometyx is now the first and only systemic treatment that is FDA-approved for previously treated neuroendocrine tumors regardless of primary tumor site, grade, somatostatin receptor expression and functional status.The approval came ahead of the target action date of April 3, 2025.The company is now focused on developing zanzalintinib, a next-generation oral TKI. In January 2025, results from an expansion cohort of the phase Ib/II STELLAR-001 study ev","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fda-expands-exelixis-cabometyx-label-190000158.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4588","LU1074936037.SGD","BAYRY","LU0321505439.SGD","LU0985481810.HKD","LU0882574055.USD","LU1093756168.USD","BMY","IE00BFXG1179.USD","IE00BSNM7G36.USD","LU0225284248.USD","LU0266512127.USD","LU1868837300.USD","LU1989771016.USD","BK4559","LU1261432733.SGD","BK4139","CRC","LU0321505868.SGD","LU0237698245.USD","LU0456854461.SGD","BK4534","RCC","LU2242646821.SGD","LU1670710661.SGD","IE00BZ1G4Q59.USD","IE00BKVL7J92.USD","LU2125154935.USD","EXEL","DTC","LU2133065610.SGD","LU1585245621.USD","LU0306806265.USD","IE00B2B36J28.USD","LU0456855351.SGD","LU0096364046.USD","IE00BFTCPJ56.SGD","LU1670710588.SGD","LU1868836757.USD","LU1868836914.USD","LU2360032135.SGD","LU1093756325.SGD","LU1323610961.USD","IE0002141913.USD","LU1718418525.SGD","LU1032466523.USD","IE0009355771.USD","LU0154236417.USD"],"gpt_icon":1},{"id":"2522361927","title":"Junshi Biosciences Announces Toripalimab’s Approval in Singapore","url":"https://stock-news.laohu8.com/highlight/detail?id=2522361927","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522361927?lang=en_us&edition=fundamental","pubTime":"2025-03-27 09:00","pubTimestamp":1743037200,"startTime":"0","endTime":"0","summary":"SHANGHAI, March  26, 2025  (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to th","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/27/3050235/0/en/Junshi-Biosciences-Announces-Toripalimab-s-Approval-in-Singapore.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4006","HCC","CR","RCC","BK4161"],"gpt_icon":0},{"id":"2522935496","title":"Exelixis Stock Rises 13.3% Year to Date: Buy, Sell or Hold?","url":"https://stock-news.laohu8.com/highlight/detail?id=2522935496","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522935496?lang=en_us&edition=fundamental","pubTime":"2025-03-27 03:00","pubTimestamp":1743015600,"startTime":"0","endTime":"0","summary":"Shares of Exelixis, Inc. EXEL have risen 13.3% year to date compared with the industry’s growth of 6.6%. The stock has also outperformed the sector and the S&P 500 Index in this timeframe.The company's upbeat performance can be attributed to its strong quarterly results, raised guidance and efforts to increase shareholders' returns.Last month, Exelixis announced a new share repurchase program of $500 million. Shares rallied following the announcement. Earlier, the company reported better-than-expected fourth-quarter results, which also drove the stock higher.Let’s delve deeper and analyze the company’s strengths and weaknesses to understand how to play the stock in such a scenario.Exelixis’ lead drug Cabometyx maintains its status as the leading tyrosine kinase inhibitor  for the treatment of renal cell carcinoma  in both the frontline immuno-oncology  +TKI market and the second-line monotherapy segment.Meanwhile, Exelixis collaborated with pharma giant Merck MRK to evaluate zanzalinti","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/exelixis-stock-rises-13-3-190000591.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BFTCPJ56.SGD","LU1430594728.SGD","LU1718418525.SGD","LU1929549753.HKD","LU0289739699.SGD","LU1037948897.HKD","LU1699723380.USD","EXEL","LU1093756325.SGD","LU1989772840.SGD","LU1670711123.USD","BK4585","BK4581","LU2023250504.SGD","LU0061475181.USD","LU0306806265.USD","LU1934455277.USD","LU0306807586.USD","LU1868837136.USD","LU1989771016.USD","LU1057294990.SGD","LU1868836914.USD","BK4550","BK4588","IE00BJT1NW94.SGD","LU1868837300.USD","CRC","BK4516","LU1934455194.USD","LU1670710661.SGD","SG9999014542.SGD","SG9999015358.SGD","LU1670710588.SGD","LU1868836591.USD","IE00BFXG1179.USD","MRK","RCC","SG9999014567.USD","BK4559","LU1989772923.USD","LU2242646821.SGD","SGXZ57979304.SGD","LU1974910355.USD","LU1037948541.HKD","SG9999015341.SGD","LU1323610961.USD","LU1941712264.USD","LU0266512127.USD","LU2133065610.SGD","BMY"],"gpt_icon":0},{"id":"2522615804","title":"Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2522615804","media":"Business Wire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522615804?lang=en_us&edition=fundamental","pubTime":"2025-03-26 21:15","pubTimestamp":1742994900,"startTime":"0","endTime":"0","summary":"– FDA approval based on the phase 3 CABINET pivotal trial, which demonstrated a statistically significant and clinically meaningful improvement in progression-free survival versus placebo –。– CABOMETYX is now the first and only systemic treatment that is FDA approved for previously treated neuroendocrine tumors regardless of primary tumor site, grade, somatostatin receptor expression and functional status –。– Exelixis is prepared to immediately support these new indications –。ALAMEDA, Calif., March 26, 2025----Exelixis, Inc.  today announced that the U.S. Food and Drug Administration  has approved CABOMETYX  for the treatment of 1) adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic neuroendocrine tumors ; and 2) adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated extra-pancreatic NET . NET","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/exelixis-announces-u-fda-approval-131500269.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B66KJ199.SGD","NCI","BK4202","BK4139","BK4190","NET","BK4613","BK4548","BK4588","RCC","IE0031619046.USD","LU2286300806.USD","EXEL","AEIS","BK4585","IE00B7SZL793.SGD","BK4560","DTC","BK4554","BK4157","BK4607","BK4532","BK4116","HCC","IE00B19Z4B17.USD","BK4006"],"gpt_icon":0},{"id":"2522070300","title":"New Money Smart Financial Coaching Program (MSFCP) Organization Empowers College Students to Take Control of Their Financial Futures with Support from JPMorganChase","url":"https://stock-news.laohu8.com/highlight/detail?id=2522070300","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522070300?lang=en_us&edition=fundamental","pubTime":"2025-03-25 22:00","pubTimestamp":1742911200,"startTime":"0","endTime":"0","summary":"MSFCP.org combines financial coaching and education into one course at colleges and universities to improve students’ credential completion and financial health. NEW YORK, March 25, 2025----JPMorganChase announced the launch of a new organization to improve financial health and academic outcomes built on the legacy of the Money Smart Financial Coaching Program . The new organization, MSFCP.org, is fiscally sponsored by FJC and supported by $1.9 million in philanthropic capital from JPMorganChase. It combines financial coaching and financial education into a post-secondary course with the potential to reach at least 1,500 students across the country, opening up new pathways to well-paying jobs after graduation.MSFCP was developed at the State University of New York Westchester Community College  and incubated by the National Council for Workforce Education  with strategic guidance and funding from the firm that focused on improving financial health and academic outcomes. JPMorganChase i","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/money-smart-financial-coaching-program-140000133.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["JPM","LU0215105999.USD","LU0267386448.USD","IE00B7SZL793.SGD","LU1084165304.USD","LU2213496289.HKD","LU0203347892.USD","IE00BWXC8680.SGD","LU0048584097.USD","BK4229","LU1670628061.USD","IE00BJLML261.HKD","IE00BHPRN162.USD","LU1496350171.SGD","LU1119994496.HKD","LU2552382215.SGD","SG9999002232.USD","LU0170899867.USD","IE00B1XK9C88.USD","LU2430703178.SGD","LU2592432038.USD","BK4090","LU0256863811.USD","RCC","LU1974910355.USD","IE00B775SV38.USD","LU0868494617.USD","WCC","LU2237443978.SGD","IE00BKVL7J92.USD","LU0971096721.USD","LU2505996681.GBP","LU0106831901.USD","LU0964807845.USD","SG9999002224.SGD","IE00B66KJ199.SGD","LU0310799852.SGD","LU0943347566.SGD","LU0942090050.USD","LU0203345920.USD","LU2430703251.USD","RTC","LU2237443622.USD","BK4195","LU2552382058.USD","LU2264538146.SGD","FMCC","IE00BDCRKT87.USD","LU1261432733.SGD","LU1064131342.USD","LU1720051017.SGD"],"gpt_icon":0},{"id":"2520317569","title":"Press Release: Trevi Therapeutics Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2520317569","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520317569?lang=en_us&edition=fundamental","pubTime":"2025-03-19 04:05","pubTimestamp":1742328300,"startTime":"0","endTime":"0","summary":"Trevi Therapeutics Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Updates. Announced positive topline data from the Phase 2a RIVER trial in patients with refractory chronic cough , making Haduvio the first therapy in clinical development to show benefit in patients with chronic cough in idiopathic pulmonary fibrosis  and RCC. Completed enrollment in the Phase 2b CORAL trial in IPF patients with chronic cough in February 2025, with topline data expected in the second quarter of 2025. patients with RCC  in March 2025. Haduvio met the primary endpoint","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","BK4099","03160","RCC","BK4139","BK4007","BK4588","BK4585","TM","BK4555","BK4604","TRVI"],"gpt_icon":0},{"id":"2519389886","title":"Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2024 and Provides a Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2519389886","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519389886?lang=en_us&edition=fundamental","pubTime":"2025-03-14 06:07","pubTimestamp":1741903620,"startTime":"0","endTime":"0","summary":"○ UCART22 Phase 1 dataset and late-stage development strategy expected in the third quarter of 2025; Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPDD) granted by FDA and ODD ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/13/3042670/0/en/Cellectis-Reports-Financial-Results-for-the-Fourth-Quarter-and-Full-Year-2024-and-Provides-a-Business-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLLS","SITC","BK4080","BK4231","EC","ODD","BK4201","BK4183","RCC","BK4139","CAR","BK4022","BK4230"],"gpt_icon":0},{"id":"2519286959","title":"Allogene Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2519286959","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519286959?lang=en_us&edition=fundamental","pubTime":"2025-03-14 04:02","pubTimestamp":1741896120,"startTime":"0","endTime":"0","summary":"Momentum Builds Across Programs with Key Data Milestones Expected in 2025Cemacabtagene Ansegedleucel (Cema-Cel): First-Line (1L) Consolidation in Large B-Cell Lymphoma (LBCL) Ongoing Pivotal Phase 2 A","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/13/3042573/0/en/Allogene-Therapeutics-Reports-Fourth-Quarter-and-Full-Year-2024-Financial-Results-and-Business-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CAR","RCC","BK4230","LENZ","BK4022","BK4139"],"gpt_icon":0},{"id":"2518772527","title":"Trevi Therapeutics to Report Fourth Quarter and Year End 2024 Financial Results and Provide a Corporate Update on March 18, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2518772527","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518772527?lang=en_us&edition=fundamental","pubTime":"2025-03-12 04:05","pubTimestamp":1741723500,"startTime":"0","endTime":"0","summary":"Conference call and webcast to be held at 4:30 p.m. ET. NEW HAVEN, Conn., March 11, 2025 /PRNewswire/ --Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio  for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis  and refractory chronic cough , today announced that senior management will host a conference call and live audio webcast on Tuesday, March 18, 2025, at 4:30 p.m. ET, to provide a corporate update and review the Company's financial results for the quarter and year ended December 31, 2024.Refractory chronic cough has no approved therapies in the U.S. and is defined as a persistent cough lasting >8weeks despite treatment for an underlying condition  and includes unexplained chronic cough. RCC affects ~2-3 million patients in the U.S. and is caused by cough reflex hypersensitivity in both the central and peripheral nerves. It is a highly debilitating disease and accompanied by a wide range o","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/trevi-therapeutics-report-fourth-quarter-200500840.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/trevi-therapeutics-report-fourth-quarter-200500840.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["RCC","BK4139","LENZ","BK4007","TRVI"],"gpt_icon":0},{"id":"2518187726","title":"TRVI Stock Soars on Meeting Primary Goal in Chronic Cough Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2518187726","media":"Zacks","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518187726?lang=en_us&edition=fundamental","pubTime":"2025-03-11 21:56","pubTimestamp":1741701360,"startTime":"0","endTime":"0","summary":"Shares of Trevi Therapeutics TRVI surged 41% yesterday after it reported positive top-line data from the phase IIa RIVER study evaluating its investigational therapy Haduvio as a potential treatment for refractory chronic cough .The study met its primary endpoint — treatment with Haduvio achieved a statistically significant reduction in the 24-hour cough frequency by 67% from baseline and 57% on a placebo-adjusted basis. Similar efficacy was also seen in Haduvio-treated patients when categorized across severity levels, with a 66% reduction in 24-hour cough frequency in patients with severe cough  and a 68% reduction in those with moderate cough . These results reinforce the drug’s potential as a broad treatment option, effectively reducing cough frequency regardless of baseline severity.Haduvio also demonstrated a strong treatment response, with 84% of patients achieving at least a 30% reduction in 24-hour cough frequency from baseline compared with 29% in the placebo group.Haduvio’s s","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/trvi-stock-soars-meeting-primary-135600582.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MRK","CRL","LU2106854487.HKD","LU0006306889.USD","RCC","IE00BJT1NW94.SGD","LU2461242641.AUD","LU2361045086.USD","LU1989772923.USD","LU1291159041.SGD","LU1989772840.SGD","IE0009355771.USD","LU1035773651.USD","LU0203347892.USD","LU1929549753.HKD","BK4588","GSK","LU1057294990.SGD","SG9999001176.SGD","IE0002141913.USD","LU1116320901.HKD","TRVI","SGXZ57979304.SGD","LU0265550946.USD","LU1061106388.HKD","IE000M9KFDE8.USD","LU1066051498.USD","LU1093756325.SGD","BK4532","LU1941712348.USD","BK4533","LU0058720904.USD","LU0320765646.SGD","LU1066051225.USD","BK4530","LU1941712264.USD","GSK.UK","IE00BSNM7G36.USD","LU1917777945.USD","IE00BJJMRZ35.SGD","LU0390134368.USD","LU0234572021.USD","LU2023250504.SGD","LU1989771016.USD","IE00B2B36J28.USD","LU2112291526.USD","SG9999015341.SGD","LU2089984988.USD","IE00BLSP4452.SGD","LU0965509283.SGD"],"gpt_icon":0},{"id":"2518827184","title":"Haduvio’s Promising Efficacy in RCC Drives Buy Rating and Increased Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2518827184","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518827184?lang=en_us&edition=fundamental","pubTime":"2025-03-10 23:15","pubTimestamp":1741619720,"startTime":"0","endTime":"0","summary":"Faisal Khurshid, an analyst from Leerink Partners, reiterated the Buy rating on Trevi Therapeutics (TRVI – Research Report). The associated price t...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/haduvios-promising-efficacy-in-rcc-drives-buy-rating-and-increased-price-target?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/haduvios-promising-efficacy-in-rcc-drives-buy-rating-and-increased-price-target?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RCC"],"gpt_icon":0},{"id":"2518083245","title":"Trevi Therapeutics Announces Positive Topline Results from the Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough","url":"https://stock-news.laohu8.com/highlight/detail?id=2518083245","media":"PR Newswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518083245?lang=en_us&edition=fundamental","pubTime":"2025-03-10 18:00","pubTimestamp":1741600800,"startTime":"0","endTime":"0","summary":"Haduvio met the primary endpoint with a statistically-significant reduction  in 24-hour cough frequency with a 57% placebo-adjusted change from baseline. Haduvio is the first and only therapy to show a statistically-significant reduction in chronic cough across both RCC and IPF patients. Patient reported and other secondary outcomes were statistically significant and consistent with the primary endpoint. NEW HAVEN, Conn.,  March 10, 2025  /PRNewswire/ -- Trevi Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio  for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis  and refractory chronic cough , is pleased to announce today positive topline results from its Phase 2a RIVER trial of Haduvio for the treatment of patients with RCC . Haduvio met the primary endpoint with a statistically-significant reduction in the objective 24-hour cough frequency of 67% from baseline and 57% on a placebo-adjusted basis","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/trevi-therapeutics-announces-positive-topline-100000072.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/trevi-therapeutics-announces-positive-topline-100000072.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LENZ","BK4588","TRVI","BK4139","BK4007","FAS","RCC","BK4585"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":42,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RCC\",params:#limit:5,,,undefined,":[{"date":"2025-07-15","symbol":"RCC","amount":0.35938,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-07-15","defaultRemindTime":1752586200000,"name":"Ready Capital Corp","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-07-30","payableDate":"2025-07-15","currency":"USD","dateTimestamp":1752552000000,"payDate":"2025-07-30"},{"date":"2025-05-08","symbol":"RCC","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1746734400000,"name":null,"time":"Post Market","dateTimestamp":1746676800000,"actualEps":null},{"date":"2025-04-15","symbol":"RCC","amount":0.35938,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-04-15","defaultRemindTime":1744723800000,"name":"Ready Capital Corp","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-30","payableDate":"2025-04-15","currency":"USD","dateTimestamp":1744689600000,"payDate":"2025-04-30"},{"market":"US","date":"2025-03-03","symbol":"RCC","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1740978000000,"reportTimeType":"pre","actualEps":null},{"date":"2025-01-15","symbol":"RCC","amount":0.35938,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-01-15","defaultRemindTime":1736951400000,"name":"Ready Capital Corp","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-01-30","payableDate":"2025-01-15","currency":"USD","dateTimestamp":1736917200000,"payDate":"2025-01-30"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RCC\",market:\"US\",,,undefined,":[{"executeDate":"2021-04-14","recordDate":"2021-04-15","paymentDate":"2021-04-30","value":0.3194444,"currency":"USD"},{"executeDate":"2021-07-14","recordDate":"2021-07-15","paymentDate":"2021-07-30","value":0.359375,"currency":"USD"},{"executeDate":"2021-10-14","recordDate":"2021-10-15","paymentDate":"2021-10-30","value":0.359375,"currency":"USD"},{"executeDate":"2022-01-13","recordDate":"2022-01-14","paymentDate":"2022-01-30","value":0.359375,"currency":"USD"},{"executeDate":"2022-04-13","recordDate":"2022-04-14","paymentDate":"2022-04-30","value":0.359375,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"RCC\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0,"hold":0.875,"sell":0.125,"strongSell":0,"meanLabel":"HOLD","meanPercent":0.875,"analysts":8,"updateTime":1741060800000}}}